Squarepoint’s Jounce Therapeutics JNCE Stock Holding History
Bought
Maintained
Sold
Other funds holding JNCE
OM
BCM
Squarepoint's JNCE Position: Q1 2023 in Review
Squarepoint sold out of Jounce Therapeutics (JNCE) in Q1 2023, closing a stake of 35,606 shares — an estimated $39.5K sold.
Squarepoint first reported a position in JNCE in Q3 2018 and held it in 9 quarters. The position peaked at $602K in Q4 2020. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.
- Squarepoint reported no remaining Jounce Therapeutics position as of Q1 2023 after selling out during the quarter.
- Squarepoint sold 35,606 Jounce Therapeutics shares in Q1 2023, an estimated $39.5K.
- Squarepoint first reported a position in Jounce Therapeutics in Q3 2018 and held it in 9 quarters.
- Squarepoint's Jounce Therapeutics position peaked at $602K in Q4 2020.
- 84 funds tracked by Wall St. Rank held Jounce Therapeutics as of Q1 2023.
Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.